Risuteganib, also known as ALG1001, is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina.
CAT No: R1894
CAS No:1307293-62-4
Synonyms/Alias:Risuteganib;Luminate;1307293-62-4;ALG1001;ALG-1001;Risuteganib [USAN];123DNA66IA;UNII-123DNA66IA;GLY-ARG-GLY-CYA-THR-PRO;Risuteganib (USAN);(2S)-1-[(2S,3R)-2-[[(2R)-2-[[2-[[(2S)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-sulfopropanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid;Glycyl-L-arginylglycyl-3-sulfo-L-alanyl-L-threonyl-L-proline;L-Proline, glycyl-L-arginylglycyl-3-sulfo-L-alanyl-L-threonyl-;Risuteganib [WHO-DD];RISUTEGANIB [INN];ALG1001 (Risuteganib);ALG-1001 HEXAPEPTIDE;CHEMBL4297529;SCHEMBL19410626;HY-P1930;DB14911;DA-70689;CS-0019633;D11436;
Chemical Name:(2S)-1-[(2S,3R)-2-[[(2R)-2-[[2-[[(2S)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-sulfopropanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid; glycyl-L-arginyl-glycyl-L-cysteyl-L-threonyl-L-proline
Risuteganib is a synthetic peptide compound known for its function as an integrin regulator, playing a pivotal role in modulating cellular adhesion and signaling pathways. Structurally characterized as an arginylglycylaspartic acid (RGD) mimetic, it interacts with integrin receptors, which are essential transmembrane proteins involved in cell-extracellular matrix (ECM) interactions. Its unique biochemical profile makes it a valuable tool for researchers investigating the molecular mechanisms underlying integrin-mediated processes, cell migration, and tissue remodeling. As a research-use-only peptide, risuteganib is particularly relevant for studies in cellular biology, extracellular matrix dynamics, and peptide-based modulation of signal transduction.
Integrin Signaling Research: Risuteganib is widely employed in the elucidation of integrin-mediated signaling pathways. By acting as a ligand or modulator for specific integrin subtypes, it enables researchers to dissect the downstream effects of integrin activation or inhibition in various cellular contexts. This application is particularly significant for understanding how integrins influence cell survival, proliferation, and migration, providing insights into the molecular basis of tissue development, wound repair, and pathological processes such as fibrosis.
Cell Adhesion and Migration Studies: The compound's ability to interact with integrin receptors makes it a valuable reagent for investigating cell adhesion, spreading, and migration on extracellular matrix components. In in vitro assays, risuteganib can be used to modulate the strength and specificity of cell-ECM interactions, facilitating the study of cytoskeletal dynamics and signaling events that govern cell motility. Such research is crucial for unraveling the mechanisms that underlie tissue morphogenesis, angiogenesis, and metastasis in cancer models.
Peptide-Integrin Interaction Assays: Risuteganib serves as a reference ligand in binding assays designed to characterize the affinity and specificity of integrin-ligand interactions. Its defined peptide sequence and receptor selectivity make it an effective control or competitor in experiments that profile integrin binding kinetics, receptor occupancy, or downstream signaling events. These assays are instrumental in screening for novel integrin modulators and in validating the functional relevance of integrin-targeted compounds in preclinical research.
Extracellular Matrix Remodeling Models: By influencing cell-ECM communication, risuteganib is used in studies modeling extracellular matrix remodeling, a process fundamental to tissue homeostasis and repair. The peptide can modulate the deposition, degradation, or reorganization of ECM proteins in cell culture systems, providing a platform to investigate the molecular drivers of matrix turnover. This application supports research into fibrosis, tissue engineering, and the development of biomimetic scaffolds for regenerative medicine.
Peptide-Based Drug Discovery: The structural and functional properties of risuteganib position it as a valuable lead compound or tool molecule in peptide-based drug discovery initiatives. Researchers utilize it to explore structure-activity relationships, optimize integrin-targeted peptide scaffolds, and design novel analogs with improved selectivity or stability. Its use in high-throughput screening and mechanistic studies accelerates the identification of new candidates for modulating integrin function in diverse biological systems.
2. Emu oil in combination with other active ingredients for treating skin imperfections
3. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die
5. Store-operated Ca2+ entry sustains the fertilization Ca2+ signal in pig eggs
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More